Clinical Trial Update: A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating MK-2206 in combination with trastuzumab and lapatinib for HER2-positive solid tumors; the trial was terminated and results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors

Drugs mentioned

• Lapatinib (Lapatinib)
• MK-2206 (MK-2206)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Solid Tumors, Breast Cancer | Phase 1 | Status: TERMINATED | Results posted: 2018-10-31